Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker

Sponsor
Sequenom, Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT00770458
Collaborator
(none)
1,000
7
18
142.9
7.9

Study Details

Study Description

Brief Summary

Validate that circulating cell free fetal nucleic acid can be used to identify a direct marker for fetal aneuploidy, particularly fetal Down Syndrome (DS), that is better than surrogate markers.

Study Design

Study Type:
Observational
Anticipated Enrollment :
1000 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker
Study Start Date :
Jun 1, 2008
Actual Primary Completion Date :
Oct 1, 2009
Actual Study Completion Date :
Dec 1, 2009

Arms and Interventions

Arm Intervention/Treatment
Pregnant women

Pregnant women that will undergo standard of care procedures to evaluate fetus for Down Syndrome

Outcome Measures

Primary Outcome Measures

  1. Compare investigational assay results for Down Syndrome to standard of care results. [3 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Subject is female

  • Subject is pregnant

  • Subject is high risk aneuploid patient undergoing genetic counseling, unltrasound screening, amniocentesis and/or CVS procedure

  • Subject is willing to provide blood specimen

Exclusion Criteria:
  • Subject is not pregnant

  • Subject is not willing to provide blood specimen

  • Subject is not haveing aneuploid screening

Contacts and Locations

Locations

Site City State Country Postal Code
1 UCSD Fetal Care & Genetics Center La Jolla California United States 92037
2 San Diego Perinatal Center San Diego California United States 92123
3 Obstetrix Medical Group of San Jose San Jose California United States 95008
4 Obstetrix Medical Group of Colorado Denver Colorado United States 80218
5 Women & Infants Providence Rhode Island United States 02903
6 A.R.U.P. Salt Lake City Utah United States 84108
7 Obstetrix Medical Group of Washington Seattle Washington United States 98104

Sponsors and Collaborators

  • Sequenom, Inc.

Investigators

  • Study Director: Allan Bombard, MD, Sequenom, Inc.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00770458
Other Study ID Numbers:
  • SQNM-Trisomy21-0100
First Posted:
Oct 10, 2008
Last Update Posted:
Jan 6, 2010
Last Verified:
Jan 1, 2010

Study Results

No Results Posted as of Jan 6, 2010